ZBH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Zimmer Biomet Holdings, Inc. (ZBH) does not present a compelling buy opportunity for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The stock lacks strong positive catalysts, has neutral technical indicators, and no significant trading signals or recent news to drive momentum. Analysts' ratings and price target revisions suggest limited upside potential in the near term.
The MACD is slightly positive at 0.331, indicating mild bullish momentum. RSI is neutral at 54.174, and moving averages are converging, suggesting no clear trend. The stock is trading near its pivot level of 88.198, with resistance at 89.913 and support at 86.482. Overall, the technical indicators are neutral.
NULL identified. No recent news or significant trading trends from hedge funds or insiders. Analysts acknowledge solid fundamentals but see limited near-term upside.
Analysts have broadly lowered price targets, citing modest Q1 performance and transitional challenges. The stock's implied volatility rank is low (3.47), suggesting limited potential for significant price movement. No recent congress trading data or influential figure activity.
Financial snapshot for the latest quarter is unavailable, but analysts noted 2.9% organic revenue growth and a modest Q1 earnings beat. However, this was below buy-side expectations, and the company is in a transitional phase.
Analysts' ratings are mixed, with most maintaining Neutral or Hold ratings. Price targets have been revised downward, with the highest target at $105 and the lowest at $83. Analysts highlight solid fundamentals but limited near-term growth and sensitivity to market shifts.
